SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Budaj Andrzej)
 

Sökning: WFRF:(Budaj Andrzej) > In patients with st...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005284naa a2200469 4500
001oai:DiVA.org:uu-418944
003SwePub
008200909s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4189442 URI
0247 a https://doi.org/10.1016/j.ahj.2020.04.0042 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a White, Harvey D.u Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.4 aut
2451 0a In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events
264 1b Elsevier BV,c 2020
338 a print2 rdacarrier
520 a BackgroundIn patients with stable coronary heart disease, it is not known whether achievement of standard of care (SOC) targets in addition to evidence-based medicine (EBM) is associated with lower major adverse cardiovascular events (MACE): cardiovascular death, myocardial infarction, and stroke.MethodsEBM use was recommended in the STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY trial. SOC targets were blood pressure (BP) <140/90 mm Hg and low-density lipoprotein-cholesterol (LDL-C) <100 mg/dL and <70 mg/dL. In patients with diabetes, glycosylated hemoglobin A1c (HbA1c) < 7% and BP of <130/80 mm Hg were recommended. Feedback to investigators about rates of EBM and SOC was provided regularly.ResultsIn 13,623 patients, 1-year landmark analysis assessed the association between EBM, SOC targets, and MACE during follow-up of 2.7 years (median) after adjustment in a Cox proportional hazards model.At 1 year, aspirin was prescribed in 92.5% of patients, statins in 97.2%, β-blockers in 79.0%, and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers in 76.9%. MACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) compared with LDL-C ≥ 100 mg/dL (hazard ratio [HR] 0.694, 95% CI 0.594-0.811) and lower with LDL-C < 70 mg/dL compared with LDL-C < 100 mg/dL (70-99 mg/dL) (HR 0.834, 95% CI 0.708-0.983). MACE was lower with HbA1c < 7% compared with HbA1c ≥ 7% (HR 0.705, 95% CI 0.573-0.866). There was no effect of BP targets on MACE.ConclusionsMACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) and even lower with LDL-C < 70 mg/dL. MACE in patients with diabetes was lower with HbA1c < 7%. Achievement of targets is associated with improved patient outcomes.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
7001 a Stewart, Ralph A. H.u Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.4 aut
7001 a Dolby, Anthony J.u Milpk Hosp, Johannesburg, South Africa.4 aut
7001 a Stebbins, Amandau Duke Clin Res Inst, Duke Med, Durham, NC USA.4 aut
7001 a Cannon, Christopher P.u Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Harvard Clin Res Inst, Boston, MA 02115 USA.4 aut
7001 a Budaj, Andrzeju Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland.4 aut
7001 a Linhart, Alesu Gen Univ Hosp, Dept Med 2, Dept Cardiovasc Med, Prague, Czech Republic.4 aut
7001 a Pais, Premu St Johns Res Inst, Bangalore, Karnataka, India.4 aut
7001 a Diaz, Rafaelu Inst Cardiovasc Rosario, Estudios Cordiol Latinoamer, Rosario, Argentina.4 aut
7001 a Steg, Philippe Gabrielu Hop Bichat Claude Bernard, AP HP, Paris, France.;Paris Univ, FACT French Alliance Cardiovasc Trials, INSERM, Paris, France.;Imperial Coll, Natl Heart & Lung Inst, Royal Brampton Hosp, London, England.4 aut
7001 a Krug-Gourley, Sueu GlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area, King Of Prussia, PA USA.4 aut
7001 a Granger, Christopher B.u Duke Clin Res Inst, Duke Med, Durham, NC USA.4 aut
7001 a Hochman, Judith S.u NYU, Dept Med, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.4 aut
7001 a Koenig, Wolfgangu Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany.;Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany.;German Ctr Cardiovasc Res, Heart Alliance, Partner Site Munich, Munich, Germany.4 aut
7001 a Harrington, Robert A.u Stanford Univ, Stanford Ctr Clin Res, Dept Med, Stanford, CA 94305 USA.4 aut
7001 a Held, Claes,d 1956-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)clahe947
7001 a Wallentin, Lars,d 1943-u Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)larswall
7102 a Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.b Milpk Hosp, Johannesburg, South Africa.4 org
7730 t American Heart Journald : Elsevier BVg 225, s. 97-107q 225<97-107x 0002-8703x 1097-6744
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-418944
8564 8u https://doi.org/10.1016/j.ahj.2020.04.004

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy